Multisystem Adverse Effects of Isotretinoin: Mechanistic Insights and Clinical Implications

Isotretinoin (13-cis-retinoic acid) remains the most effective systemic therapy for severe acne, exerting its therapeutic action through modulation of retinoic acid (RAR) and retinoid X (RXR) receptors that regulate cell differentiation, apoptosis, and lipid metabolism. However, these same receptor-mediated pathways underlie a range of multisystem adverse effects. This review provides an updated synthesis of isotretinoin’s systemic toxicity profile, focusing on mechanistic insights and clinical relevance. Mucocutaneous reactions such as cheilitis and xerosis are the most frequent and predictable effects, reflecting sebaceous suppression. Hepatic enzyme elevations and dyslipidemia occur in a dose-dependent yet reversible manner, necessitating routine laboratory surveillance. Musculoskeletal, ocular, and neuropsychiatric effects are infrequent, generally mild, and self-limiting, though psychiatric monitoring remains advisable in predisposed individuals. Gastrointestinal and endocrine disturbances, including subclinical hypothyroidism, have been reported but lack strong causal evidence. Hematologic and renal alterations are minor and transient. The most critical safety concern remains isotretinoin’s potent teratogenicity, emphasizing the need for strict contraceptive protocols and post-therapy washout periods. Overall, isotretinoin’s adverse effects largely reflect its pharmacodynamic actions and are manageable through individualized dosing and systematic monitoring. Understanding the mechanisms and risk factors underlying these reactions is essential for optimizing therapeutic safety and patient outcomes.